Bayer’s Monsanto unit is seeking final approval from a Missouri state court for a $7.25 billion settlement intended to resolve nearly all current and future U.S. claims alleging that Roundup caused non-Hodgkin lymphoma. Judge Timothy Boyer will review the agreement and hear objections from plaintiffs’ attorneys who say it could force clients into terms that limit their ability to pursue trials, alongside lawyers who support the framework as the best route to compensation. Boyer is not expected to rule immediately. Bayer faces approximately 65,000 claims in state and federal courts, with proposed payments ranging from $10,000 to $165,000 based on factors including cancer severity, age at diagnosis and exposure circumstances. Bayer rejects the allegations and says decades of research show glyphosate is safe. The litigation has weighed on Bayer since its 2018 acquisition of Monsanto, while a 2020 settlement worth approximately $10 billion resolved many existing cases but left future claims outstanding. The approval effort follows a Supreme Court ruling in Bayer’s favor that weakened a central failure-to-warn theory in the litigation. Scientific assessments remain divided: the World Health Organization’s International Agency for Research on Cancer classified glyphosate as a probable carcinogen in 2015, while the U.S. Environmental Protection Agency has found it is not likely to cause cancer in humans and expects to complete an updated risk assessment in late 2026.